Tezacaftor

CFTR corrector

Phase of research

FDA-/EMA-approved for Cystic Fibrosis

How it helps

Restore CFTR Function

General information

N/A

Synonyms

VX-661

Marketed as

Dietary sources

N/A

Structure not available

C26H27F3N2O6

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
F508del/A455E
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/R352Q
2 41.78
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis humans 4.29 In combination with ivacaftor as Symdeko®.
F508del/F1052V
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/D1270N
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/Q493X
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
L997F/R258G
1 4.12
Link Tested on Impact factor Notes
Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. human cell cultures 4.12
F508del/S945L
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/R117C
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/G85E
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
F508del/N1303K
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
F508del/R347H
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/E56K
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
S1435Gfs14X
1 5.22
Link Tested on Impact factor Notes
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis human cell cultures 5.22 Alone or in combination with lumacaftor.
F508del/R1070W
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/E831X
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/3120+1G->A
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
F508del/2184delA
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
E831X
1 5.22
Link Tested on Impact factor Notes
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis human cell cultures 5.22 Alone or in combination with lumacaftor. Even better when followed by treatment with ivacaftor.
F508del/3659delC
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
F508del/E193K
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
Q1476X
1 5.22
Link Tested on Impact factor Notes
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis human cell cultures 5.22 In combination with lumacaftor.
F508del/I507del
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
F508del/G542X
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
F508del/R553X
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
F508del/F1074L
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/K1060T
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/R347P
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
F508del/3272-26A->G
2 41.78
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis humans 4.29 In combination with ivacaftor as Symdeko®.
E1418Rfs14X
1 5.22
Link Tested on Impact factor Notes
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis human cell cultures 5.22 Alone or in combination with lumacaftor. Followed by treatment with ivacaftor.
F508del/D1152H
3 29.22
Link Tested on Impact factor Notes
Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. human cell cultures 4.12
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis humans 4.29 In combination with ivacaftor as Symdeko®.
F508del/711+3A->G
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/2184insA
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
F508del/R1162X
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
S1455X
1 5.22
Link Tested on Impact factor Notes
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis human cell cultures 5.22 In combination with lumacaftor.
F508del/R560T
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
F508del/1898+1G->A
4 70.67
Link Tested on Impact factor Notes
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
F508del/3849+10kbC->T
2 41.78
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis humans 4.29 In combination with ivacaftor as Symdeko®.
F508del/394delTT
1 4.12
Link Tested on Impact factor Notes
Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. human cell cultures 4.12
F508del/R74W
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
E1418X
2 5.22
Link Tested on Impact factor Notes
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis human cell cultures 5.22 Alone or in combination with lumacaftor.
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis human cell cultures 5.22 Alone or in combination with lumacaftor. Better in combination with ivacaftor.
F508del/W1282X
4 70.67
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
F508del/D579G
2 41.78
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis humans 4.29 In combination with ivacaftor as Symdeko®.
F508del/S977F
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/F508del
9 40.92
Link Tested on Impact factor Notes
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis humans 4.29 In combination with ivacaftor as Symdeko®.
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del humans 79.26 In combination with ivacaftor as Symdeko®.
Study of VX-661 combined with ivacaftor in adults with cystic fibrosis (Vertex VX-661-103) humans N/A In combination with ivacaftor as Symdeko®.
Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR humans 16.49 Better in combination with ivacaftor as Symdeko®.
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. humans 70.67 In combination with ivacaftor. Better in combination with ivacaftor plus elexacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. human cell cultures 4.12
F508del/D110H
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/621+1G->T
4 48.85
Link Tested on Impact factor Notes
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis humans 5.22 In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
F508del/2789+5G->A
2 41.78
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis humans 4.29 In combination with ivacaftor as Symdeko®.
F508del/P67L
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/D110E
1 79.26
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
F508del/L206W
2 41.78
Link Tested on Impact factor Notes
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Phe508del and a Residual Function Mutation humans 79.26 In combination with ivacaftor as Symdeko®. Better than ivacaftor alone.
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis humans 4.29 In combination with ivacaftor as Symdeko®.
F508del/G551D
1 16.49
Link Tested on Impact factor Notes
Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR humans 16.49 Better in combination with ivacaftor as Symdeko®.
F508del/1717-1G->A
5 48.49
Link Tested on Impact factor Notes
Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. human cell cultures 4.12
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with ivacaftor and VX-659.
Phase 2 study of VX-440 combination drug in people with cystic fibrosis (Vertex VX-440-101) humans N/A In combination with VX-440 and ivacaftor.
Phase 2 study of VX-152 combination drug in people with cystic fibrosis (Vertex VX-152-102) humans N/A In combination with VX-152 and ivacaftor.
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles humans 70.67 In combination with elexacaftor and ivacaftor.

Does not treat

Mutation Number of sources Average impact factor
F508del/4016insT
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/1717-1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/S341P6
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/2183AA->G
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/2183delAA->G
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/Q290X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/W1089X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/L1065P
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/3850-3T->G
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/1677delTA
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/A46D6
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/C276X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/E585X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/S1255X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/Q493X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/Q525X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/3876delA
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/T338I8
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/3905insT
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/K710X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/G85E
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/N1303K
2 4.12
Link Tested on Impact factor Notes
Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. human cell cultures 4.12
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
Link Tested on Impact factor Notes
Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. human cell cultures 4.12
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/V520F
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/1154insTC
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/1811+1.6kbA->G
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/574delA
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/1341+1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/541delC
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/L732X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/R785X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/Q220X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/3007delG
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/R709X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/2347delG
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/3120+1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/Y569D6
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/2143delT
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/3737delA
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/2184delA
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/3791delC
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/S466X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/3659delC
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/405+1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/Y122X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/CFTRdel2,3
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/E822X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/S1196X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/R1066C
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/R764X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/I507del
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/G542X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/R553X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/R1158X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/G330X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/R560S
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/R347P
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/2307insA
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/E92X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/A561E
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/1078delT
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/E60X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/A559T6
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/4040delA
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/W57X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/711+5G->A
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/3120G->A
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/L218X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/Q98X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/E1104X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/3600+2insT
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/2184insA
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/H1085R6
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/W1204X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/711+1G->T
2 4.12
Link Tested on Impact factor Notes
Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. human cell cultures 4.12
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
Link Tested on Impact factor Notes
Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. human cell cultures 4.12
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/1812-1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/406-1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/2711delT
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/G673X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/1248+1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/Q414X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/R1162X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/S489X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
Q1412X
1 5.22
Link Tested on Impact factor Notes
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis human cell cultures 5.22 Not even in combination with lumacaftor.
F508del/R560T
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/Q1313X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/4005+1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/712-1G->T
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/1898+1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/394delTT
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/Q39X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/457TAT->G
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/663delT
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/R792X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/4374+1G->T
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/W496X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/R851X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/W1282X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/L1077P6
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/S434X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/405+3A->C
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/4382delA7
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/2622+1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/2869insG
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/1811+1G->C
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/3850-1G->A
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/R75X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/R1066M
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/L927P
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/M1101K
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
Q1390X
1 5.22
Link Tested on Impact factor Notes
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis human cell cultures 5.22 Not even in combination with lumacaftor.
F508del/621+1G->T
2 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/Q552X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/2043delG
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/S912X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/W846X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/W401X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/Y1092X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/Q890X
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/CFTRdele22-23
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.
F508del/L467P6
1 0.00
Link Tested on Impact factor Notes
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis (Vertex VX-661-107) humans N/A In combination with ivacaftor as Symdeko®.